SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP notifies investors of Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ:AMLX) that a securities class action lawsuit has been filed.
The complaint filed in this class action alleges that all the Class Period, Defendants made materially false and/or misleading, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose investors that: (1) Defendants had overstated RELYVRIO's commercial prospects; (2) patients were discontinuing treatment with RELYVRIO after six months; (3) the rate at that new patients starting treatment with RELYVRIO was decreasing; (4) accordingly, Defendants had also overstated RELYVRIO's prescription rate; (5) Defendants attempted to hide the market trends frompositive about the ...